Amedeo Smart

Free Medical Literature Service


 

Amedeo

Multiple Sclerosis

  Free Subscription

Articles published in
PLoS One
    January 2022
  1. HORTON MK, McCurdy S, Shao X, Bellesis K, et al
    Case-control study of adverse childhood experiences and multiple sclerosis risk and clinical outcomes.
    PLoS One. 2022;17:e0262093.
    >> Share

  2. SARPONG-KUMANKOMAH S, Knox KB, Kelly ME, Hunter G, et al
    Quantification of human plasma metalloproteins in multiple sclerosis, ischemic stroke and healthy controls reveals an association of haptoglobin-hemoglobin complexes with age.
    PLoS One. 2022;17:e0262160.
    >> Share

  3. WIJEYARATNAM DO, Edwards T, Pilutti LA, Cressman EK, et al
    Assessing visually guided reaching in people with multiple sclerosis with and without self-reported upper limb impairment.
    PLoS One. 2022;17:e0262480.
    >> Share

  4. AL-KAFAJI G, Bakheit HF, AlAli F, Fattah M, et al
    Next-generation sequencing of the whole mitochondrial genome identifies functionally deleterious mutations in patients with multiple sclerosis.
    PLoS One. 2022;17:e0263606.
    >> Share

  5. CHOI S, Spini M, Hua J, Harrison DM, et al
    Correction: Blood-brain barrier breakdown in non-enhancing multiple sclerosis lesions detected by 7-Tesla MP2RAGE DeltaT1 mapping.
    PLoS One. 2022;17:e0264452.
    >> Share

  6. KOKAS Z, Sandi D, Fricska-Nagy Z, Fuvesi J, et al
    Do Hungarian multiple sclerosis care units fulfil international criteria?
    PLoS One. 2022;17:e0264328.
    >> Share

  7. SHOBEIRI P, Karimi A, Momtazmanesh S, Teixeira AL, et al
    Exercise-induced increase in blood-based brain-derived neurotrophic factor (BDNF) in people with multiple sclerosis: A systematic review and meta-analysis of exercise intervention trials.
    PLoS One. 2022;17:e0264557.
    >> Share

  8. CORTESI PA, Antonazzo IC, Gasperini C, Nica M, et al
    Cost-effectiveness and budget impact analysis of siponimod in the treatment of secondary progressive multiple sclerosis in Italy.
    PLoS One. 2022;17:e0264123.
    >> Share

  9. MIKKELSEN AP, Egerup P, Kolte AM, Westergaard D, et al
    Pregnancy loss and risk of multiple sclerosis and autoimmune neurological disorder: A nationwide cohort study.
    PLoS One. 2022;17:e0266203.
    >> Share

  10. MIRMOSAYYEB O, Ebrahimi N, Barzegar M, Afshari-Safavi A, et al
    Olfactory dysfunction in patients with multiple sclerosis; A systematic review and meta-analysis.
    PLoS One. 2022;17:e0266492.
    >> Share

  11. ROMERO-PINEL L, Bau L, Matas E, Leon I, et al
    Cost associated with a relapse-free patient in multiple sclerosis: A real-world health indicator.
    PLoS One. 2022;17:e0267504.
    >> Share

  12. WILSON-MENZFELD G, Naisby J, Baker K, Morris R, et al
    Yoga provision for individuals living with Multiple Sclerosis: Is the future online?
    PLoS One. 2022;17:e0266786.
    >> Share

  13. YADAV M, Ali S, Shrode RL, Shahi SK, et al
    Multiple sclerosis patients have an altered gut mycobiome and increased fungal to bacterial richness.
    PLoS One. 2022;17:e0264556.
    >> Share

  14. BIERNACKI T, Sandi D, Fuvesi J, Fricska-Nagy Z, et al
    The safety and efficacy of fingolimod: Real-world data from a long-term, non-interventional study on the treatment of RRMS patients spanning up to 5 years from Hungary.
    PLoS One. 2022;17:e0267346.
    >> Share

  15. GIOVANNETTI AM, Pakenham KI, Presti G, Quartuccio ME, et al
    A group resilience training program for people with multiple sclerosis: Study protocol of a multi-centre cluster-randomized controlled trial (multi-READY for MS).
    PLoS One. 2022;17:e0267245.
    >> Share

  16. BOIS A, Tervil B, Moreau A, Vienne-Jumeau A, et al
    A topological data analysis-based method for gait signals with an application to the study of multiple sclerosis.
    PLoS One. 2022;17:e0268475.
    >> Share

  17. ALVAREZ-RODRIGUEZ E, Sanchez-Franco CM, Perez-Haro MJ, Bello-Otero L, et al
    Development of a scale for the evaluation of the quality of the shared decision process in multiple sclerosis patients.
    PLoS One. 2022;17:e0268125.
    >> Share

  18. KOFFMAN J, Penfold C, Cottrell L, Farsides B, et al
    "I wanna live and not think about the future" what place for advance care planning for people living with severe multiple sclerosis and their families? A qualitative study.
    PLoS One. 2022;17:e0265861.
    >> Share

  19. ELKHALII-WILHELM S, Sippel A, Riemann-Lorenz K, Kofahl C, et al
    Experiences of persons with Multiple Sclerosis with lifestyle adjustment-A qualitative interview study.
    PLoS One. 2022;17:e0268988.
    >> Share

  20. RASKIN E, Achiron A, Zloto O, Neuman R, et al
    Uveitis prior to clinical presentation of Multiple Sclerosis (MS) is associated with better MS prognosis.
    PLoS One. 2022;17:e0264918.
    >> Share

  21. PETRZALKA M, Meluzinova E, Libertinova J, Mojzisova H, et al
    IL-2, IL-6 and chitinase 3-like 2 might predict early relapse activity in multiple sclerosis.
    PLoS One. 2022;17:e0270607.
    >> Share

  22. KRAUSE A, Lee K, Konig D, Faist M, et al
    Six weeks of whole-body vibration improves fine motor accuracy, functional mobility and quality of life in people with multiple sclerosis.
    PLoS One. 2022;17:e0270698.
    >> Share

  23. ZANOTTO T, Rice LA, Sosnoff JJ
    Frailty among people with multiple sclerosis who are wheelchair users.
    PLoS One. 2022;17:e0271688.
    >> Share

  24. VITTURI BK, Rahmani A, Dini G, Montecucco A, et al
    Spatial and temporal distribution of the prevalence of unemployment and early retirement in people with multiple sclerosis: A systematic review with meta-analysis.
    PLoS One. 2022;17:e0272156.
    >> Share

  25. TU H, Li N, Liu W, Fan Z, et al
    Effects of transcutaneous tibial nerve stimulation on females with overactive bladder syndrome in multiple sclerosis a protocol for a systematic review and meta-analysis.
    PLoS One. 2022;17:e0269371.
    >> Share

  26. ABUAF AF, Bunting SR, Klein S, Carroll T, et al
    Analysis of the extent of limbic system changes in multiple sclerosis using FreeSurfer and voxel-based morphometry approaches.
    PLoS One. 2022;17:e0274778.
    >> Share

  27. KUENDIG S, Kool J, Polhemus A, Schallert W, et al
    Three weeks of rehabilitation improves walking capacity but not daily physical activity in patients with multiple sclerosis with moderate to severe walking disability.
    PLoS One. 2022;17:e0274348.
    >> Share

  28. NING L, Wang B
    Neurofilament light chain in blood as a diagnostic and predictive biomarker for multiple sclerosis: A systematic review and meta-analysis.
    PLoS One. 2022;17:e0274565.
    >> Share

    January 2021
  29. JOHNSON DK, Reynolds KM, Poole BD, Montierth MD, et al
    Contribution of viral infection to risk for cancer in systemic lupus erythematosus and multiple sclerosis.
    PLoS One. 2021;16:e0243150.
    >> Share

  30. THALER C, Kyselyova AA, Faizy TD, Nawka MT, et al
    Heterogeneity of multiple sclerosis lesions in fast diffusional kurtosis imaging.
    PLoS One. 2021;16:e0245844.
    >> Share

  31. WILSKI M, Brola W, Luniewska M, Tomczak M, et al
    The perceived impact of multiple sclerosis and self-management: The mediating role of coping strategies.
    PLoS One. 2021;16:e0248135.
    >> Share

  32. GOODIN DS, Khankhanian P, Gourraud PA, Vince N, et al
    The nature of genetic and environmental susceptibility to multiple sclerosis.
    PLoS One. 2021;16:e0246157.
    >> Share

  33. PRIDHAM G, Hossain S, Rawji KS, Zhang Y, et al
    A metric learning method for estimating myelin content based on T2-weighted MRI from a de- and re-myelination model of multiple sclerosis.
    PLoS One. 2021;16:e0249460.
    >> Share

  34. GOUJON A, Mirafzal S, Zuber K, Deschamps R, et al
    3D-Fast Gray Matter Acquisition with Phase Sensitive Inversion Recovery Magnetic Resonance Imaging at 3 Tesla: Application for detection of spinal cord lesions in patients with multiple sclerosis.
    PLoS One. 2021;16:e0247813.
    >> Share

  35. CHOI S, Spini M, Hua J, Harrison DM, et al
    Blood-brain barrier breakdown in non-enhancing multiple sclerosis lesions detected by 7-Tesla MP2RAGE DeltaT1 mapping.
    PLoS One. 2021;16:e0249973.
    >> Share

  36. GOLAN D, Sagiv S, Glass-Marmor L, Miller A, et al
    Mobile-phone-based e-diary derived patient reported outcomes: Association with clinical disease activity, psychological status and quality of life of patients with multiple sclerosis.
    PLoS One. 2021;16:e0250647.
    >> Share

  37. KLISTORNER S, Barnett MH, Wasserthal J, Yiannikas C, et al
    Differentiating axonal loss and demyelination in chronic MS lesions: A novel approach using single streamline diffusivity analysis.
    PLoS One. 2021;16:e0244766.
    >> Share

  38. PAPP V, Buron MD, Siersma V, Rasmussen PV, et al
    Real-world outcomes for a complete nationwide cohort of more than 3200 teriflunomide-treated multiple sclerosis patients in The Danish Multiple Sclerosis Registry.
    PLoS One. 2021;16:e0250820.
    >> Share

  39. KOENIG KA, Beall EB, Sakaie KE, Ontaneda D, et al
    Evaluation of a connectivity-based imaging metric that reflects functional decline in Multiple Sclerosis.
    PLoS One. 2021;16:e0251338.
    >> Share

  40. CARTER B, Hayes C, Smith A, Pennington A, et al
    A single patient reported outcome measure for acquired brain injury, multiple sclerosis & Parkinson's disease.
    PLoS One. 2021;16:e0251484.
    >> Share

  41. ROGACZEWSKA M, Michalak S, Stopa M
    Macular vessel density differs in multiple sclerosis and neuromyelitis optica spectrum disorder: An optical coherence tomography angiography study.
    PLoS One. 2021;16:e0253417.
    >> Share

  42. BSTEH G, Assar H, Hegen H, Heschl B, et al
    COVID-19 severity and mortality in multiple sclerosis are not associated with immunotherapy: Insights from a nation-wide Austrian registry.
    PLoS One. 2021;16:e0255316.
    >> Share

  43. GOODIN DS, Oksenberg JR, Douillard V, Gourraud PA, et al
    Genetic susceptibility to multiple sclerosis in African Americans.
    PLoS One. 2021;16:e0254945.
    >> Share

  44. SERAJI M, Mohebbi M, Safari A, Krekelberg B, et al
    Multiple sclerosis reduces synchrony of the magnocellular pathway.
    PLoS One. 2021;16:e0255324.
    >> Share

  45. GAJ S, Ontaneda D, Nakamura K
    Automatic segmentation of gadolinium-enhancing lesions in multiple sclerosis using deep learning from clinical MRI.
    PLoS One. 2021;16:e0255939.
    >> Share

  46. NG KEE KWONG KC, Mollison D, Meijboom R, York EN, et al
    The prevalence of paramagnetic rim lesions in multiple sclerosis: A systematic review and meta-analysis.
    PLoS One. 2021;16:e0256845.
    >> Share

  47. SANTISTEBAN L, Teremetz M, Irazusta J, Lindberg PG, et al
    Outcome measures used in trials on gait rehabilitation in multiple sclerosis: A systematic literature review.
    PLoS One. 2021;16:e0257809.
    >> Share

  48. MOCCIA M, Affinito G, Capacchione A, Lanzillo R, et al
    Interferon beta for the treatment of multiple sclerosis in the Campania Region of Italy: Merging the real-life to routinely collected healthcare data.
    PLoS One. 2021;16:e0258017.
    >> Share

  49. MECA-LALLANA JE, Oreja-Guevara C, Munoz D, Olascoaga J, et al
    Four-year safety and effectiveness data from patients with multiple sclerosis treated with fingolimod: The Spanish GILENYA registry.
    PLoS One. 2021;16:e0258437.
    >> Share

  50. STERNBACH S, West N, Singhal NK, Clements R, et al
    The BHMT-betaine methylation pathway epigenetically modulates oligodendrocyte maturation.
    PLoS One. 2021;16:e0250486.
    >> Share

  51. ROZYCKA J
    How I see is how I feel. Identification of illness perception schema and its association with adaptation outcomes in multiple sclerosis - a 5-year prospective study.
    PLoS One. 2021;16:e0258740.
    >> Share

  52. ALKETBI A, Basit S, Hamza N, Walton LM, et al
    The added value of cognition-targeted exercise versus symptom-targeted exercise for multiple sclerosis fatigue: A randomized controlled pilot trial.
    PLoS One. 2021;16:e0258752.
    >> Share

  53. KRUGER K, Fricke LM, Dilger EM, Thiele A, et al
    How is and how should healthcare for people with multiple sclerosis in Germany be designed?-The rationale and protocol for the mixed-methods study Multiple Sclerosis-Patient-Oriented Care in Lower Saxony (MS-PoV).
    PLoS One. 2021;16:e0259855.
    >> Share

  54. VERES G, Vas NF, Lyngby Lassen M, Beresova M, et al
    Effect of grey-level discretization on texture feature on different weighted MRI images of diverse disease groups.
    PLoS One. 2021;16:e0253419.
    >> Share

  55. MARRIE RA, Walld R, Bolton JM, Sareen J, et al
    Effect of comorbid mood and anxiety disorders on breast and cervical cancer screening in immune-mediated inflammatory disease.
    PLoS One. 2021;16:e0249809.
    >> Share

  56. MIMPEN M, Rolf L, Poelmans G, van den Ouweland J, et al
    Vitamin D related genetic polymorphisms affect serological response to high-dose vitamin D supplementation in multiple sclerosis.
    PLoS One. 2021;16:e0261097.
    >> Share

  57. ZANGENEH Z, Abdi-Ali A, Khamooshian K, Alvandi A, et al
    Bacterial variation in the oral microbiota in multiple sclerosis patients.
    PLoS One. 2021;16:e0260384.
    >> Share

  58. SAPOSNIK G, Del Rio B, Bueno-Gil G, Sempere AP, et al
    Behavioral aspects of nurse practitioners associated with optimal multiple sclerosis care in Spain.
    PLoS One. 2021;16:e0261050.
    >> Share

  59. VALORI M, Jansson L, Tienari PJ
    CD8+ cell somatic mutations in multiple sclerosis patients and controls-Enrichment of mutations in STAT3 and other genes implicated in hematological malignancies.
    PLoS One. 2021;16:e0261002.
    >> Share

  60. AHMAD I, Wergeland S, Oveland E, Bo L, et al
    A higher proportion of ermin-immunopositive oligodendrocytes in areas of remyelination.
    PLoS One. 2021;16:e0256155.
    >> Share

    January 2020
  61. HJORTH M, Dandu N, Mellergard J
    Treatment effects of fingolimod in multiple sclerosis: Selective changes in peripheral blood lymphocyte subsets.
    PLoS One. 2020;15:e0228380.
    >> Share

  62. GIOVANNETTI AM, Pietrolongo E, Borreani C, Giordano A, et al
    Conversion to secondary progressive multiple sclerosis: Multistakeholder experiences and needs in Italy.
    PLoS One. 2020;15:e0228587.
    >> Share

  63. GRANER M, Pointon T, Manton S, Green M, et al
    Oligoclonal IgG antibodies in multiple sclerosis target patient-specific peptides.
    PLoS One. 2020;15:e0228883.
    >> Share

  64. SELGRADE BP, Meyer D, Sosnoff JJ, Franz JR, et al
    Can optical flow perturbations detect walking balance impairment in people with multiple sclerosis?
    PLoS One. 2020;15:e0230202.
    >> Share

  65. SECCIA R, Gammelli D, Dominici F, Romano S, et al
    Considering patient clinical history impacts performance of machine learning models in predicting course of multiple sclerosis.
    PLoS One. 2020;15:e0230219.
    >> Share

  66. AKAISHI T, Takahashi T, Fujihara K, Misu T, et al
    Number of MRI T1-hypointensity corrected by T2/FLAIR lesion volume indicates clinical severity in patients with multiple sclerosis.
    PLoS One. 2020;15:e0231225.
    >> Share

  67. BARRERO F, Mallada-Frechin J, Martinez-Gines ML, Marzo ME, et al
    Spanish real-world experience with fingolimod in relapsing-remitting multiple sclerosis patients: MS NEXT study.
    PLoS One. 2020;15:e0230846.
    >> Share

  68. GIOVANNETTI AM, Quintas R, Tramacere I, Giordano A, et al
    A resilience group training program for people with multiple sclerosis: Results of a pilot single-blind randomized controlled trial and nested qualitative study.
    PLoS One. 2020;15:e0231380.
    >> Share

  69. SILVA T, Fragoso YD, Destro Rodrigues MFS, Gomes AO, et al
    Effects of photobiomodulation on interleukin-10 and nitrites in individuals with relapsing-remitting multiple sclerosis - Randomized clinical trial.
    PLoS One. 2020;15:e0230551.
    >> Share

  70. HASHEMI R, Hosseini-Asl SS, Arefhosseini SR, Morshedi M, et al
    The impact of vitamin D3 intake on inflammatory markers in multiple sclerosis patients and their first-degree relatives.
    PLoS One. 2020;15:e0231145.
    >> Share

  71. MASUDA H, Mori M, Uzawa A, Uchida T, et al
    Difference in fatigue and pain between neuromyelitis optica spectrum disorder and multiple sclerosis.
    PLoS One. 2020;15:e0224419.
    >> Share

  72. PARRAVICINI C, Lecca D, Marangon D, Coppolino GT, et al
    Development of the first in vivo GPR17 ligand through an iterative drug discovery pipeline: A novel disease-modifying strategy for multiple sclerosis.
    PLoS One. 2020;15:e0231483.
    >> Share

  73. GOITIA B, Bruno D, Abrevaya S, Sedeno L, et al
    The relationship between executive functions and fluid intelligence in multiple sclerosis.
    PLoS One. 2020;15:e0231868.
    >> Share

  74. SAURI-SUAREZ S, Quinones-Aguilar S, Contreras-Marin A, Ramiro-Guerrero EO, et al
    Adherence to self-administering interferon-beta1a using RebiSmart(R) device in Mexican patients with relapsing multiple sclerosis.
    PLoS One. 2020;15:e0230959.
    >> Share

  75. OHLMEIER C, Gothe H, Haas J, Osowski U, et al
    Epidemiology, characteristics and treatment of patients with relapsing remitting multiple sclerosis and incidence of high disease activity: Real world evidence based on German claims data.
    PLoS One. 2020;15:e0231846.
    >> Share

  76. GOUGH N, Brkan L, Subramaniam P, Chiuccariello L, et al
    Feasibility of remotely supervised transcranial direct current stimulation and cognitive remediation: A systematic review.
    PLoS One. 2020;15:e0223029.
    >> Share

  77. GOLDMAN MD, Dwyer L, Coleman R, Sohn MW, et al
    Patient-specific factors modulate leukocyte response in dimethyl fumarate treated MS patients.
    PLoS One. 2020;15:e0228617.
    >> Share

  78. KUSNIEROVA P, Zeman D, Hradilek P, Zapletalova O, et al
    Determination of chitinase 3-like 1 in cerebrospinal fluid in multiple sclerosis and other neurological diseases.
    PLoS One. 2020;15:e0233519.
    >> Share

  79. BROWN FS, Glasmacher SA, Kearns PKA, MacDougall N, et al
    Systematic review of prediction models in relapsing remitting multiple sclerosis.
    PLoS One. 2020;15:e0233575.
    >> Share

  80. BAUER A, Lechner I, Auer M, Berger T, et al
    Influence of physical activity on serum vitamin D levels in people with multiple sclerosis.
    PLoS One. 2020;15:e0234333.
    >> Share

  81. LUCCHETTA RC, Leonart LP, Goncalves MVM, Becker J, et al
    Reliability in long-term clinical studies of disease-modifying therapies for relapsing-remitting multiple sclerosis: A systematic review.
    PLoS One. 2020;15:e0231722.
    >> Share

  82. JULIAN GS, Rosim RP, Carneseca EC, Rigolon J, et al
    Annualized hospitalization rate with natalizumab vs fingolimod in second-line treatment for RRMS in the public healthcare system in Brazil: A claim database approach.
    PLoS One. 2020;15:e0229768.
    >> Share

  83. CHERAGHMAKANI H, Baghbanian SM, HabibiSaravi R, Azar A, et al
    Age and sex-adjusted incidence and yearly prevalence of multiple sclerosis (MS) in Mazandaran province, Iran: An 11-years study.
    PLoS One. 2020;15:e0235562.
    >> Share

  84. ROTSTEIN DL, Marrie RA, Tu K, Schultz SE, et al
    Health service utilization in immigrants with multiple sclerosis.
    PLoS One. 2020;15:e0234876.
    >> Share

  85. NINOU I, Sevastou I, Magkrioti C, Kaffe E, et al
    Genetic deletion of Autotaxin from CD11b+ cells decreases the severity of experimental autoimmune encephalomyelitis.
    PLoS One. 2020;15:e0226050.
    >> Share

  86. FARCI R, Carta A, Cocco E, Frau J, et al
    Optical coherence tomography angiography in multiple sclerosis: A cross-sectional study.
    PLoS One. 2020;15:e0236090.
    >> Share

  87. ILJICSOV A, Milanovich D, Ajtay A, Oberfrank F, et al
    Incidence and prevalence of multiple sclerosis in Hungary based on record linkage of nationwide multiple healthcare administrative data.
    PLoS One. 2020;15:e0236432.
    >> Share

  88. KEMMERER CL, Pernpeintner V, Ruschil C, Abdelhak A, et al
    Differential effects of disease modifying drugs on peripheral blood B cell subsets: A cross sectional study in multiple sclerosis patients treated with interferon-beta, glatiramer acetate, dimethyl fumarate, fingolimod or natalizumab.
    PLoS One. 2020;15:e0235449.
    >> Share

  89. CAVERZASI E, Cordano C, Zhu AH, Zhao C, et al
    Imaging correlates of visual function in multiple sclerosis.
    PLoS One. 2020;15:e0235615.
    >> Share

  90. PAMPHLETT R, Mak R, Lee J, Buckland ME, et al
    Concentrations of toxic metals and essential trace elements vary among individual neurons in the human locus ceruleus.
    PLoS One. 2020;15:e0233300.
    >> Share

  91. SINHA S, Renavikar PS, Crawford MP, Steward-Tharp SM, et al
    Altered expression of SIRPgamma on the T-cells of relapsing remitting multiple sclerosis and type 1 diabetes patients could potentiate effector responses from T-cells.
    PLoS One. 2020;15:e0238070.
    >> Share

  92. MORALES PANTOJA IE, Smith MD, Rajbhandari L, Cheng L, et al
    iPSCs from people with MS can differentiate into oligodendrocytes in a homeostatic but not an inflammatory milieu.
    PLoS One. 2020;15:e0233980.
    >> Share

  93. SOUZA KM, Diniz IM, Lemos LLP, Junior NGR, et al
    Effectiveness of first-line treatment for relapsing-remitting multiple sclerosis in Brazil: A 16-year non-concurrent cohort study.
    PLoS One. 2020;15:e0238476.
    >> Share

  94. ALNAJASHI H, Jabbad R
    Behavioral practices of patients with multiple sclerosis during Covid-19 pandemic.
    PLoS One. 2020;15:e0241103.
    >> Share

  95. COTTRELL L, Economos G, Evans C, Silber E, et al
    A realist review of advance care planning for people with multiple sclerosis and their families.
    PLoS One. 2020;15:e0240815.
    >> Share

  96. MELNIKOV M, Sharanova S, Sviridova A, Rogovskii V, et al
    The influence of glatiramer acetate on Th17-immune response in multiple sclerosis.
    PLoS One. 2020;15:e0240305.
    >> Share

  97. PERLEJEWSKI K, Bukowska-Osko I, Rydzanicz M, Dzieciatkowski T, et al
    Search for viral agents in cerebrospinal fluid in patients with multiple sclerosis using real-time PCR and metagenomics.
    PLoS One. 2020;15:e0240601.
    >> Share

  98. ZHANG X, Gao B, Xu B
    No association between the vitamin D-binding protein (DBP) gene polymorphisms (rs7041 and rs4588) and multiple sclerosis and type 1 diabetes mellitus: A meta-analysis.
    PLoS One. 2020;15:e0242256.
    >> Share

  99. BEREK K, Hegen H, Auer M, Zinganell A, et al
    Cerebrospinal fluid oligoclonal bands in Neuroborreliosis are specific for Borrelia burgdorferi.
    PLoS One. 2020;15:e0239453.
    >> Share

  100. NIKOLIC B, Ivancevic N, Zaletel I, Rovcanin B, et al
    Characteristics of pediatric multiple sclerosis: A tertiary referral center study.
    PLoS One. 2020;15:e0243031.
    >> Share

  101. CORDON B, Vilades E, Orduna E, Satue M, et al
    Angiography with optical coherence tomography as a biomarker in multiple sclerosis.
    PLoS One. 2020;15:e0243236.
    >> Share

  102. VICKARYOUS N, Jitlal M, Jacobs BM, Middleton R, et al
    Remote testing of vitamin D levels across the UK MS population-A case control study.
    PLoS One. 2020;15:e0241459.
    >> Share

    January 2019
  103. JONGEN PJ, van Mastrigt GA, Heerings M, Visser LH, et al
    Effect of an intensive 3-day social cognitive treatment (can do treatment) on control self-efficacy in patients with relapsing remitting multiple sclerosis and low disability: A single-centre randomized controlled trial.
    PLoS One. 2019;14:e0223482.
    >> Share

  104. AMATO MP, Prestipino E, Bellinvia A, Niccolai C, et al
    Cognitive impairment in multiple sclerosis: An exploratory analysis of environmental and lifestyle risk factors.
    PLoS One. 2019;14:e0222929.
    >> Share

  105. WORMSBECKER AE, Johnson C, Bourns L, Harris T, et al
    Demonstration of background rates of three conditions of interest for vaccine safety surveillance.
    PLoS One. 2019;14:e0210833.
    >> Share

  106. AMATO MP, Prestipino E, Bellinvia A, Niccolai C, et al
    Correction: Cognitive impairment in multiple sclerosis: An exploratory analysis of environmental and lifestyle risk factors.
    PLoS One. 2019;14:e0225494.
    >> Share

  107. BOQUETE L, Lopez-Guillen E, Vilades E, Miguel-Jimenez JM, et al
    Diagnostic ability of multifocal electroretinogram in early multiple sclerosis using a new signal analysis method.
    PLoS One. 2019;14:e0224500.
    >> Share

  108. CORTINI A, Bembich S, Marson L, Cocco E, et al
    Identification of novel non-myelin biomarkers in multiple sclerosis using an improved phage-display approach.
    PLoS One. 2019;14:e0226162.
    >> Share

  109. BURKILL S, Vattulainen P, Geissbuehler Y, Sabido Espin M, et al
    The association between exposure to interferon-beta during pregnancy and birth measurements in offspring of women with multiple sclerosis.
    PLoS One. 2019;14:e0227120.
    >> Share

  110. EHLING R, Amprosi M, Kremmel B, Bsteh G, et al
    Second language learning induces grey matter volume increase in people with multiple sclerosis.
    PLoS One. 2019;14:e0226525.
    >> Share

  111. POSTIGO-ALONSO B, Galvao-Carmona A, Conde-Gavilan C, Jover A, et al
    The effect of prioritization over cognitive-motor interference in people with relapsing-remitting multiple sclerosis and healthy controls.
    PLoS One. 2019;14:e0226775.
    >> Share

  112. MELIS M, Littera R, Cocco E, Frau J, et al
    Entropy of human leukocyte antigen and killer-cell immunoglobulin-like receptor systems in immune-mediated disorders: A pilot study on multiple sclerosis.
    PLoS One. 2019;14:e0226615.
    >> Share

  113. LEE SU, Li CF, Mortales CL, Pawling J, et al
    Increasing cell permeability of N-acetylglucosamine via 6-acetylation enhances capacity to suppress T-helper 1 (TH1)/TH17 responses and autoimmunity.
    PLoS One. 2019;14:e0214253.
    >> Share

  114. TEMPLETON N, Kivell B, McCaughey-Chapman A, Connor B, et al
    Clozapine administration enhanced functional recovery after cuprizone demyelination.
    PLoS One. 2019;14:e0216113.
    >> Share

  115. LANDTBLOM AM, Guala D, Martin C, Olsson-Hau S, et al
    RebiQoL: A randomized trial of telemedicine patient support program for health-related quality of life and adherence in people with MS treated with Rebif.
    PLoS One. 2019;14:e0218453.
    >> Share

  116. GAJAMANGE S, Shelton A, Clough M, White O, et al
    Functional correlates of cognitive dysfunction in clinically isolated syndromes.
    PLoS One. 2019;14:e0219590.
    >> Share

  117. KAPICA-TOPCZEWSKA K, Tarasiuk J, Collin F, Brola W, et al
    The effectiveness of interferon beta versus glatiramer acetate and natalizumab versus fingolimod in a Polish real-world population.
    PLoS One. 2019;14:e0223863.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016